Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

ruxolitinib 23Cyclophosphamide 13Whole-Body Irradiation 10Tacrolimus 9Mycophenolic Acid 9fludarabine phosphate 8fludarabine 8Stem Cell Transplantation 8Specimen Handling 7Peripheral Blood Stem Cell Transplantation 7Busulfan 5Azacitidine 5navitoclax 4Sirolimus 4Melphalan 4Biopsy 4luspatercept 3fedratinib 3Methotrexate 3Cyclosporine 3venetoclax 2selinexor 2parsaclisib 2letermovir 2itacitinib 2bomedemstat 2Injections 2INCB057643 2INCB039110 2Hematopoietic Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × INCB059872 × 1 year × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡